@entity618 plus XXXX for inducing remission of Henoch-Sch  nlein purpura nephritis: a retrospective study.

@entity1 @entity644 @entity6071 @entity7774 @entity229 @entity2098 @entity618
OBJECTIVE: The treatment of Henoch-Sch  nlein purpura (HSP) with moderate @entity644 remains controversial. We retrospectively analyzed the efficacy of immune suppressants, with a particular emphasis on @entity618 ( @entity2098 ). METHODS: Ninety-five HSP @entity1 with moderate @entity644 (1.0-3.5 g/24 h) after at least three months of therapy with @entity7774 -converting enzyme inhibitor (ACEI) or @entity6071 ( @entity6071 ) were divided into three groups: an @entity2098 group (n=33) that received @entity2098 1.0-1.5 g/d combined with @entity229 (0.4-0.5 mg/(kg  d)), a corticosteroid (CS) group (n=31) that received full-dose @entity229 (0.8-1.0 mg/(kg  d)), and a control group (n=31). @entity1 in the @entity2098 and CS groups continued to take ACEI or @entity6071 at the original dose. The @entity1 in the control group continued to take ACEI or @entity6071 but the dose was increased by (1.73  0.58)-fold. The @entity1 were followed up for 6-78 months (median 28 months). RESULTS: The baseline @entity644 was higher in the @entity2098 group ((2.1  0.9) g/24 h) than in the control group ((1.6  0.8) g/24 h) (P=0.039). The @entity644 decreased significantly in all groups during follow-up, but only in the @entity2098 group did it decrease significantly after the first month. At the end of follow-up, the @entity644 was (0.4  0.7) g/24 h in the @entity2098 group and (0.4  0.4) g/24 h in the CS group, significantly lower than that in the control group ((0.9  1.1) g/24 h). The remission rates in the @entity2098 group, CS group, and control group were respectively 72.7%, 71.0%, and 48.4% at six months and 72.7%, 64.5%, and 45.2% at the end of follow-up. The overall number of reported adverse events was 17 in the @entity2098 group, 30 in the CS group, and 6 in the control group (P<0.001). CONCLUSIONS: @entity2098 with low-dose @entity229 may be as effective as full-dose @entity229 and tend to have fewer adverse events. Therefore, it is probably superior to conservative treatments of adult HSP @entity1 with moderate @entity644 .
